









Markets
/
Stocks
/
nasdaq-ncna
/

NuCana PLC

NCNA

3.630USD

-0.310-7.87%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

124.64KMarket Cap

LossP/E TTM



NuCana PLC

3.630

-0.310-7.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NuCana PLC

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NuCana PLC's Score

Industry at a Glance

Industry Ranking

304 / 501

Overall Ranking

582 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

25.000

Target Price

+2764.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NuCana PLC Highlights

StrengthsRisks

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Fairly Valued

The company’s latest PE is -0.12, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.62K shares, increasing 29.61% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.33.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

NuCana PLC's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.12, which is -180.70% below the recent high of 0.10 and -57719.71% above the recent low of -68.92.

Score

Industry at a Glance

Previous score

7.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 304/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04. The average price target for NuCana PLC is 25.00, with a high of 25.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 5.84, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 6.43 and the support level at 3.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.97

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.334

Sell

RSI(14)

40.144

Neutral

STOCH(KDJ)(9,3,3)

13.296

Oversold

ATR(14)

0.372

Low Volatility

CCI(14)

-99.839

Neutral

Williams %R

99.020

Oversold

TRIX(12,20)

-0.655

Sell

StochRSI(14)

2.991

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

3.848

Sell

MA10

4.023

Sell

MA20

4.689

Sell

MA50

4.209

Sell

MA100

2.552

Buy

MA200

1.610

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 0.24%, representing a quarter-over-quarter increase of 66.37%. The largest institutional shareholder is Baillie Gifford, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Glass Jacobson Wealth Advisors

75.00

Scientech Research LLC

1.27K

Sofinnova Investments, Inc

998.00

Abingworth Management Limited

667.00

Baader Bank AG

495.00

+890.00%

Cetera Investment Advisers LLC

412.00

Qube Research & Technologies Ltd

357.00

LPL Financial LLC

100.00

Jump Financial, LLC

84.00

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.